pharmaceutical clinical trials

Experimental blood thinner cuts risk of stroke recurrence by 26%: Bayer | Health News

Ravi Singh8 hours ago02 mins

Bayer said on Thursday its experimental blood thinner cut the risk of stroke recurrence by 26% in a late-stage trial, in a fresh boost for CEO Bill Anderson’s turnaround efforts. The German group said the read-out came from a Phase III study comparing a combination of standard antiplatelet therapy and Bayer’s asundexian with…

► Necessary Cookies Standard

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

None

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

None

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

None

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

None